Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region (CROSBI ID 200994)

Prilog u časopisu | pregledni rad (stručni)

Vrdoljak, Eduard ; Ciuleanu, T. ; Kharkevich, G. ; Mardiak, J. ; Mego, M. ; Padrik, P. ; Petruželka, L. ; Purkalne, G. ; Shparyk, Y. ; Skrbinc, B. et al. Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region // Expert opinion on pharmacotherapy, 13 (2012), 2; 159-174. doi: 10.1517/14656566.2012.647406

Podaci o odgovornosti

Vrdoljak, Eduard ; Ciuleanu, T. ; Kharkevich, G. ; Mardiak, J. ; Mego, M. ; Padrik, P. ; Petruželka, L. ; Purkalne, G. ; Shparyk, Y. ; Skrbinc, B. ; Szczylik, C. ; Torday, L.

engleski

Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region

INTRODUCTION: Belarus, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Republic of Moldova, Romania, Russian Federation, Serbia, Slovakia, Slovenia and the Ukraine represent a collection of Central and Eastern European (CEE) countries in which the epidemiology and treatment of cancer varies greatly between and within countries. Current challenges include non-adherence to current treatment guidelines, restrictions in access and reimbursement for new therapies, and a lack of basic oncology programs. Metastatic renal cell carcinoma (mRCC) is a malignancy with historically poor prognosis. In CEE countries, the incidence and mortality rates of mRCC are among the highest in the world. Fortunately, mRCC represents a cancer for which a number of new targeted therapies have recently demonstrated benefit, resulting in new evidence-based treatment guidelines. Incorporating these mRCC treatment recommendations into the routine care of patients with mRCC in CEE countries would represent a major step forward for cancer care in this region. AREAS COVERED: This review discusses the unique challenges faced by the aforementioned Eastern European countries in the treatment of metastatic renal cell cancer, in an attempt to assist health-care providers in providing the best care possible for their European patients. EXPERT OPINION: Despite a wealth of clinical trial data supporting the use of targeted therapies for first-line treatment of mRCC, cytokine-based immunotherapy is still used in some of these European countries. With implementation and adherence to existing guidelines, treatment can be clinically and economically optimized in patients with mRCC from this region.

tretment; metastatic renal cancer; Central and Eastern European region

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

13 (2)

2012.

159-174

objavljeno

1465-6566

10.1517/14656566.2012.647406

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost